Repare Therapeutics (RPTX) News Today → A new way to collect income from stocks (From DTI) (Ad) Free RPTX Stock Alerts $3.15 -0.15 (-4.55%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuationmarkets.businessinsider.com - April 22 at 9:30 AMBloom Burton Upgrades Repare Therapeutics (NASDAQ:RPTX) to "Buy"americanbankingnews.com - April 21 at 1:34 AMRepare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the bruntfinance.yahoo.com - April 20 at 10:40 AMRepare Therapeutics (NASDAQ:RPTX) Rating Increased to Buy at Bloom Burtonmarketbeat.com - April 20 at 7:22 AMLloyd Mitchell Segal Sells 2,491 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) Stockinsidertrades.com - April 2 at 4:26 AMRepare therapeutics exec sells shares worth $7,000investing.com - March 29 at 10:12 AMInsider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells 2,650 Shares of Stockinsidertrades.com - March 28 at 8:48 AMRepare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells $12,693.50 in Stockinsidertrades.com - March 28 at 8:48 AMRPTX Apr 2024 7.500 callfinance.yahoo.com - March 16 at 9:56 AMRPTX Jul 2024 7.500 callfinance.yahoo.com - March 16 at 9:56 AMRepare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbusinesswire.com - March 15 at 2:35 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXprnewswire.com - March 11 at 8:00 PMBuy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Aheadmarkets.businessinsider.com - March 8 at 11:35 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXprnewswire.com - March 3 at 10:15 AMRepare Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 1 at 8:25 AMRepare Therapeutics to Participate in Two Upcoming Investor Conferencesbusinesswire.com - February 29 at 7:05 AMSHAREHOLDER ALERT: Potential Recovery for Repare Therapeutics Inc. (RPTX) Investorsmsn.com - February 28 at 11:48 PMRecap: Repare Therapeutics Q4 Earningsbenzinga.com - February 28 at 1:45 PMRepare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023finance.yahoo.com - February 28 at 8:44 AMRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Resultsbusinesswire.com - February 28 at 7:05 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXprnewswire.com - February 24 at 10:00 AMStrong Buy: Repare Therapeutics’ Promising Clinical Outcomes in Cancer Therapymarkets.businessinsider.com - February 22 at 1:12 PMWe're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Ratefinance.yahoo.com - February 17 at 1:42 PMRPTX Mar 2024 7.500 callfinance.yahoo.com - February 17 at 2:12 AMKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)businesswire.com - February 16 at 7:02 PMKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)businesswire.com - February 16 at 6:28 PMRepare Therapeutics Inc. (NASDAQ:RPTX) to Post Q2 2024 Earnings of ($0.96) Per Share, HC Wainwright Forecastsmarketbeat.com - February 16 at 8:33 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXprnewswire.com - February 15 at 6:10 PMRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664finance.yahoo.com - February 15 at 8:59 AMBloom Burton Downgrades Repare Therapeutics (NASDAQ:RPTX) to Accumulatemarketbeat.com - February 15 at 7:39 AMFY2023 EPS Estimates for Repare Therapeutics Inc. (NASDAQ:RPTX) Cut by Analystmarketbeat.com - February 15 at 7:37 AMRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664businesswire.com - February 15 at 7:05 AMRepare Therapeutics Inc (RPTX)investing.com - February 15 at 12:50 AMEBS Sep 2024 7.500 putfinance.yahoo.com - February 15 at 12:50 AMEBS Jun 2024 1.000 putfinance.yahoo.com - February 15 at 12:50 AMHC Wainwright Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $10.00marketbeat.com - February 14 at 8:25 AMRoche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Monthmsn.com - February 13 at 12:38 PMBuy Rating on Repare Therapeutics: Solid Financials and Promising Oncology Pipeline Despite Roche Setbackmarkets.businessinsider.com - February 13 at 12:38 PMRepare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?finance.yahoo.com - February 13 at 7:38 AMRepare to regain global rights to camonsertib from Rochemsn.com - February 12 at 9:19 PMRepare Therapeutics to Regain Global Rights to Camonsertibfinance.yahoo.com - February 12 at 4:19 PMAnalysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Repare Therapeutics (RPTX)markets.businessinsider.com - January 26 at 5:08 PMRepare Therapeutics Gets $40 Mln Milestone Payment From Roche Towards Developing Camonsertibmarkets.businessinsider.com - January 25 at 9:19 AMRepare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Paymentfinance.yahoo.com - January 25 at 9:19 AMRepare Therapeutics Inc. (NASDAQ:RPTX) to Post FY2028 Earnings of $0.79 Per Share, Capital One Financial Forecastsmarketbeat.com - January 22 at 2:23 AMRepare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestonesfinance.yahoo.com - January 8 at 9:36 AMDebiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancerbusinesswire.com - January 4 at 7:25 PMRepare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancerfinance.yahoo.com - January 4 at 7:25 PMRepare Therapeutics Stock (NASDAQ:RPTX) Earnings Dates and Earning Callsbenzinga.com - November 24 at 7:59 AMRepare Therapeutics Stock (NASDAQ:RPTX) Dividends: History, Yield and Datesbenzinga.com - November 24 at 7:59 AM Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him RPTX Media Mentions By Week RPTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPTX News Sentiment▼0.760.41▲Average Medical News Sentiment RPTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPTX Articles This Week▼52▲RPTX Articles Average Week Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Nuvectis Pharma News OptiNose News Vistagen Therapeutics News CytomX Therapeutics News Eliem Therapeutics News Karyopharm Therapeutics News Citius Pharmaceuticals News Coya Therapeutics News FibroGen News Societal CDMO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
